• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA to review re-submitted application for Sorrento’s lidocaine patch

September 12, 2017 By Sarah Faulkner

Scilex PharmaceuticalsSorrento Therapeutics (NSDQ:SRNE) subsidiary Scilex Pharmaceuticals said today that the FDA has received the resubmitted version of a new drug application for its lidocaine patch, ZTlido.

The San Diego, Calif.-based company is developing the drug-device product for the relief of pain associated with post-herpetic neuralgia.

The FDA said it is slated to finish reviewing the company’s NDA by February 28th next year. SRNE shares were trading at $1.85 apiece today in mid-afternoon activity, up 1.4%.

If the product wins approval by the FDA, the company has said it could be ready for its U.S. commercial launch in 2018. Sorrento also reportedly plans to submit a marketing authorization application for ZTlido in Europe in the fourth quarter of this year.

Sorrento’s anhydrous patch contains just 36 milligrams of lidocaine, compared to reference products Lidoderm and Versatis, which each have 700 milligrams of the painkiller.

In June, the company touted data from a head-to-head clinical adhesion study of its ZTlido lidocaine patch, comparing it to Versatis.

The study’s primary endpoint was to demonstrate statistically significant non-inferior mean adhesion at each of the pre-determined time points. In 44 healthy volunteers, the researchers assessed adhesion at 0, 3, 6, 9 and 12 hours. Adhesion was scored using an EMA scale ranging from 6, being greater than 95% adhesion, and a score of 0, meaning significant adhesion failure.

ZTlido had superior adhesion compared to Versatis, with mean adhesion scores of 5.35 and 3.59 respectively. At the end of the 12-hour time period, ZTlido had a mean adhesion score of 5.006 and Versatis had a mean adhesion score of 2.268.

Two participants had complete detachment with Versatis, but there were no detachments in the ZTlido group. There was also no statistically significant difference in the mean dermal irritation scores between the 2 products.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Scilex Pharmaceuticals, Sorrento Therapeutics

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS